Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series.

This study shows a partial efficacy of rituximab in renal function recovery and a low risk of infectious complications in patients with MPO vasculitis with severe renal involvement, in particular in the short term. The optimal treatment in this subgroup of patients still has to be established because data are lacking.